Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial

BackgroundChronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated peripheral neuropathy that is currently classified into several clinical subtypes, which are presumed to have different pathogenic mechanisms. Recently, studies identified a subgroup of patients with CID...

Full description

Bibliographic Details
Main Authors: Shimizu, Shinobu, Iijima, Masahiro, Fukami, Yuki, Tamura, Natsuko, Nakatochi, Masahiro, Ando, Masahiko, Nishi, Ryoji, Koike, Haruki, Kaida, Kenichi, Koga, Michiaki, Kanda, Takashi, Ogata, Hidenori, Kira, Jun-Ichi, Mori, Masahiro, Kuwabara, Satoshi, Katsuno, Masahisa
Format: Article
Language:English
Published: JMIR Publications 2020-04-01
Series:JMIR Research Protocols
Online Access:https://www.researchprotocols.org/2020/4/e17117

Internet

https://www.researchprotocols.org/2020/4/e17117

Similar Items